Among the series of deals secured by multinational corporations at the 6th China International Import Expo (CIIE), Italy-based Chiesi Farmaceutici S.p.A. has inked a partnership with Shanghai Pharmaceuticals Co., Ltd (SHA: 601607, HKG: 2607). This strategic alliance aims to capitalize on Shanghai Pharmaceutical’s extensive distribution network. As reported by Shine, the collaboration will encompass new product launches, importation, warehousing, logistics, distribution, retail, hospital coverage, and market penetration.
Chiesi’s COPD Therapy and Market Expansion
The initial focus of the partnership will be on Chiesi’s chronic obstructive pulmonary disorder (COPD) therapy, Riarify (beclomethasone, formoterol, glycopyrronium bromide), which entered the Chinese market in April 2022 and was subsequently included in the National Reimbursement Drug List (NRDL) from March this year. This inclusion is expected to boost the therapy’s accessibility and affordability for patients in China.
Teva Pharmaceutical’s Partnership with Zhejiang International Group
In another significant deal at CIIE, Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) signed an agreement with Zhejiang International Group. The partnership will leverage Zhejiang International Group’s retail channel capabilities, particularly in the context of Teva’s recent approval in China for the antiseptic healing cream Sudocrem. Teva aims to introduce a range of other over-the-counter self-care consumer products to the Chinese market.
Cowell Health’s Collaborations with Novartis and AstraZeneca
Additionally, several deals were signed with Cowell Health, a China-based health and disease management company with a strong presence in retailing, general practitioner services, and pharmacies. New partners joining Cowell Health’s network include Novartis (NYSE: NVS) and AstraZeneca (AZ, NASDAQ: AZN), as reported by ThePaper. These collaborations are set to strengthen Cowell Health’s position in the Chinese healthcare market.- Flcube.com
